Brown, Lisle/Cummings, Inc. Moderna, Inc. Transaction History
Brown, Lisle/Cummings, Inc.
- $307 Billion
- Q2 2024
A detailed history of Brown, Lisle/Cummings, Inc. transactions in Moderna, Inc. stock. As of the latest transaction made, Brown, Lisle/Cummings, Inc. holds 1,535 shares of MRNA stock, worth $92,407. This represents 0.06% of its overall portfolio holdings.
Number of Shares
1,535
Previous 1,535
-0.0%
Holding current value
$92,407
Previous $164 Million
11.44%
% of portfolio
0.06%
Previous 0.06%
Shares
3 transactions
Others Institutions Holding MRNA
# of Institutions
1,112Shares Held
241MCall Options Held
9.26MPut Options Held
12.1M-
Baillie Gifford & CO43.4MShares$2.62 Billion4.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA39.6MShares$2.38 Billion0.09% of portfolio
-
Black Rock Inc. New York, NY25.6MShares$1.54 Billion0.07% of portfolio
-
State Street Corp Boston, MA15MShares$904 Million0.08% of portfolio
-
Theleme Partners LLP London, X07.23MShares$435 Million42.67% of portfolio
About Moderna, Inc.
- Ticker MRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 391,200,000
- Market Cap $23.6B
- Description
- Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...